Leveraging Non-Dilutive Funding for Drug Discovery & Development

• Drug development is a long, multi-year process, starting with preclinical research and advancing through early and late-stage clinical trials before reaching the market. 

• Early-stage funding primarily comes from non-dilutive sources such as grants, which can de-risk projects and support innovative research. 

• Later-stage clinical development often requires significant capital, where venture capital (VC) or industrial partnerships become more relevant. 

• Non-dilutive funding is sometimes still available for late-stage clinical trials, though opportunities are more limited compared to early-stage support. 

• IPOs are becoming less common, and venture capital is increasingly selective. 

• Less than 1% of startups secure VC funding, which typically takes 6–9 months to obtain. 

• Early-stage biotech companies often face a “valley of death” where promising projects cannot advance due to lack of funding. 

• Only 300–400 mergers occur annually, so acquisition is rarely an early-stage funding solution. 

• Non-dilutive funding (primarily grants) does not require giving up equity or selling shares, allowing founders to maintain control. 

• Supports high-risk, early-stage innovation that may not appeal to VCs or private equity. 

• Billions of dollars are available annually from government and non-government organizations interested in public health. 

• Non-dilutive funding is underutilized by many biotech startups despite accessibility. 

• Grant applications are complex and time-intensive, requiring deep knowledge of funding agencies. 

• Early-stage researchers (academia): Use grants to fund discovery research and generate foundational IP; industrial partnerships are possible but less common. 

• For-profit organizations/startups: Leverage grants to de-risk programs, then use VC and industrial partnerships to advance promising candidates to later-stage development. 

• Grants often support specific tasks, from compound screening to clinical trials. 

• Understanding which grant mechanisms align with project stage and needs is crucial. 

• WinSanTor: Funded by NIH SBIR Fast Track grants starting in 2014; used successive non-dilutive grants to complete preclinical work and three Phase 2 trials; currently in Phase 3. 

• Cybrexa: Leveraged NIH SBIR grants to support R&D milestones, FDA approvals, and ultimately secure industrial collaborations. 

• Astrocyte Pharmaceuticals: Used multiple NIH grants and foundation funding to advance neuroprotection therapies; Phase 1 study initiated in 2022. 

• Key takeaway: Non-dilutive funding validates technology and attracts further investment. 

• Federal Government: 

• • NIH SBIR/STTR: Supports small business R&D with commercial potential; awards range from $300,000 to over $3 million per project. 

• • CDMRP: Focuses on high-risk, high-gain research for military-relevant diseases; funding ranges from $300,000 to >$16 million. 

• • BARDA: Broad Agency Announcements (BAA) fund medical countermeasures; Drive program provides $750,000 initial awards, follow-up up to $20 million; new VITAL accelerator awards $50,000–$200,000. 

• • ARPA-H: Focuses on audacious, interdisciplinary biomedical projects; funds large, high-risk/high-reward programs. 

• State Agencies: 

• • CPRIT (Texas): Over 2,000 awards, total >$3.6B; largest award >$20M; supports Phase 1 clinical trials or projects near IND filing. 

• • CIRM (California): Largest regenerative medicine funder; over $24B awarded; largest single award >$50M; supports Phase 1–3 trials. 

• Foundations: 

• • ADDF: Funds high-risk Alzheimer’s therapeutics; venture philanthropy model; total >$290M awarded. 

• • Michael J. Fox Foundation: Supports Parkinson’s research; awarded >$309M; typical awards $1–2M, up to $6M for therapeutic development. 

General Steps to Prepare a Grant Application 

• Identify eligible funding opportunities aligned with your project stage and goals. 

• Understand the agency’s expectations, mission, and review criteria. 

• Prepare a clear, concise project plan with realistic milestones and timelines. 

• Write a strong, well-organized proposal emphasizing significance, innovation, and feasibility. 

• Seek feedback from colleagues and domain experts before submission. 

• Submit on time and follow up to demonstrate commitment. 

Identify a Suitable Funding Opportunity 

• Connect with program officers/directors via webinars, conferences, or pre-application meetings. 

• Ensure alignment between project scope and funding agency’s mission goals. 

• Determine the appropriate mechanism (e.g., SBIR vs. STTR, Phase I vs. Phase II, non-SBIR grants). 

Understand the Level of Funding for Your Development Milestones 

• Map funding mechanisms to project milestones (e.g., NCI Phase I: $400K; Phase II: $2M; Phase 2B or CRP: up to $4M). 

• Ensure proposed budget is feasible and aligned with technical plan. 

• Include quantitative, measurable metrics to allow reviewers to evaluate success. 

Have a Clear Understanding of Funding Agency’s Expectations 

• Address unmet medical needs; focus on conditions not adequately treated. 

• Highlight innovation and intellectual property strategy. 

• Demonstrate rigor in study design and account for biological variables. 

• Present the scientific premise, including strengths, weaknesses, and a plan to address gaps. 

• Consider regulatory requirements and agency-specific definitions of success. 

• Non-dilutive funding is widely available to support all stages of drug discovery and development. 

• Align project stage with appropriate funding mechanisms to meet milestones efficiently. 

• Consult program directors to gain insight into agency priorities and expectations. 

• Pre-applications are often required and have earlier deadlines than full applications. 

• Expert guidance, such as from EGC, can improve grant competitiveness and increase chances of success.